Kynam Capital Management
$1.8B 13F equity value
40 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Kynam Capital Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| CLDX | CELLDEX THERAPEUTICS INC NEW | 5,322,908 | $198M | 10.9% |
| SNDX | SYNDAX PHARMACEUTICALS INC | 8,050,959 | $176M | 9.7% |
| PCVX | VAXCYTE INC | 2,922,335 | $170M | 9.4% |
| COGT | COGENT BIOSCIENCES INC | 3,667,097 | $142M | 7.8% |
| VERA | VERA THERAPEUTICS INC | 2,890,059 | $124M | 6.9% |
| VRDN | VIRIDIAN THERAPEUTICS INC | 6,453,877 | $119M | 6.6% |
| TVTX | TRAVERE THERAPEUTICS INC | 2,000,000 | $114M | 6.3% |
| BEAM | BEAM THERAPEUTICS INC | 2,840,792 | $97M | 5.4% |
| URGN | UROGEN PHARMA LTD | 2,434,207 | $90M | 5.0% |
| LEGN | LEGEND BIOTECH CORP | 3,001,205 | $87M | 4.8% |
Track Kynam Capital Management's 13F portfolio: $1.8B in reported holdings, 40 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}